RE: Does lower inflation mean better times ahead for small cap investors?29 Jul 2023 21:20
Thank you for this. This gives me more confidence indeed and everything points to some good news soon. The way this is written sounds very promising for all 3 products. GLA
Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals (LSE:HEMO), a biopharmaceutical company pioneering new therapies and treatments for blood diseases, may be close to gaining permission from US regulators for Phase I clinical trials of its HEMO-CAR-T therapy, a groundbreaking treatment for acute myeloid leukaemia.
The company has also advanced its proprietary Chimeric Bait Receptor (CBR) platform technology, which uses synthetic biology and artificial intelligence to program immune cells to eliminate viral infections by destroying the viruses that cause them.
HEMO’s research focuses on the development of accessible treatments for blood cancers, severe autoimmune diseases like multiple sclerosis, aplastic anemia, and systemic lupus erythematosus. The company is developing proprietary HEMO-CAR-T immune therapy, a treatment in which a patient’s own immune cells are modified to recognise and kill cancer cells. Use of these cells eliminates the need for chemotherapy or radiation and their toxic side effects. The company is seeking permission from the US Federal Drugs Administration (FDA) to proceed to Phase I clinical trials for both the HEMO-CAR-T and CDX antibodies. The company is currently responding to an FDA request for amendments to the treatment.
While pressing ahead with HEMO-CAR-T the company has made significant progress towards developing its CBR technology. The platform was evolved in the course of HEMO’s cell cancer research, which indicated how cell therapy approaches might be used to treat major existing and emerging viral infections. CBR identifies protective cells and molecules including macrophages and interferon that can be activated to kill virus infected cells and protect against viruses including SARS-CoV-2, Dengue, Ebola, Marburg, Zika and Chikungunya.
HEMO has also continued developing its other major pipeline asset, the CDX antibody the company hopes will provide an alternative means of treating leukaemia and of conditioning patients for bone marrow transplants. Early last year it entered into a service agreement with Selexis to develop a ‘master cell line’ that will be used to produce CDX antibodies for future clinical trials and patient treatments.
HEMO’s road to getting the green light from the FDA has been a long one, but the company remains confident it can satisfy the regulator’s requirements. HEMO’s proposal is a compelling one, but as with all biotech innovators, patient is the watchword for investors. At the time of writing the company’s share price was 1.5p and its market cap £17m.